CNRS - AIX MARSEILLE UNIV: UMR7257

Home page > en > Research > Teams > Viral Replicases: Structure, function and drug-design

Viral Replicases: Structure, function and drug-design

Head Bruno CANARD

Latest Publications

  1. Filovirus proteins for antiviral drug discovery: Structure/function of proteins involved in assembly and budding. (2018) Martin B, Reynard O, Volchkov V, Decroly E. Antiviral Res 150 183-192 PMID:29305306
  2. Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA. (2018) Ferron F, Subissi L, Silveira De Morais AT, Le NTT, Sevajol M, Gluais L, Decroly E, Vonrhein C, Bricogne G, Canard B, Imbert I. Proc Natl Acad Sci U S A 115 E162-E171 PMID:29279395
  3. Toscana virus nucleoprotein oligomer organization observed in solution. (2017) Baklouti A, Goulet A, Lichiere J, Canard B, Charrel RN, Ferron F, Coutard B, Papageorgiou N. Acta Crystallogr D Struct Biol 73 650-659 PMID:28777080
  4. Toward the identification of viral cap-methyltransferase inhibitors by fluorescence screening assay. (2017) Aouadi W, Eydoux C, Coutard B, Martin B, Debart F, Vasseur JJ, Contreras JM, Morice C, Querat G, Jung ML, Canard B, Guillemot JC, Decroly E. Antiviral Res 144 330-339 PMID:28676301
  5. Antiviral activity of [1,2,3]triazolo[4,5-d]pyrimidin-7(6H)-ones against chikungunya virus targeting the viral capping nsP1. (2017) Gigante A, Gomez-SanJuan A, Delang L, Li C, Bueno O, Gamo AM, Priego EM, Camarasa MJ, Jochmans D, Leyssen P, Decroly E, Coutard B, Querat G, Neyts J, Perez-Perez MJ. Antiviral Res. 144 216-222 PMID:28619679
  6. Biochemical principles and inhibitors to interfere with viral capping pathways. (2017) Decroly E, Canard B. Curr Opin Virol 24 87-96 PMID:28527860
...All publications

Our team seeks to unravel the molecular mechanisms of emerging viruses by characterizing the structures and the enzymatic activities of proteins forming the viral replication and transcription complex. These studies are a prerequisite for the development of specific inhibitors of these enzymes and should allow the development of new antiviral strategies.

RNA viruses are often associated with the emergence of infectious diseases. Among the best known, epidemics related to Ebola, SARS coronavirus and MERS, chikungunya or dengue virus illustrate the worldwide public health concern related to viral infections. The team "Viral replicase: structure, mechanism and drug-design" characterizes enzymes and proteines from emerging viruses involved in the replication of their genome and transcription of their messenger RNAs. These enzymes are associated in a replication/transcription complex (RTC). Our studies focus not only on viral polymerases that are at the heart viral replication, but also on the enzymes involved in RNA modifications such as capping and proofreading and proteins involved in the regulation of replication. Beyond the study of the RTC, we are also interested in the interplay of these enzymes with the innate immunity defence mechanism of the cell. The viral replication proteins are privileged antiviral targets and understanding of their structure and function is essential for the design of antiviral molecules with a high potential. To support these research projects, the lab benefits from the support of an inhibitor-screening platform (PCML) and a platform dedicated to the expression of recombinant viral proteins.


Sarah ATTOUMANI
Bruno CANARD
Bruno COUTARD
Etienne DECROLY
Cécilia EYDOUX
Véronique FATTORINI
Ana-Sofia FERREIRA-RAMOS
François FERRON
Jean-Claude GUILLEMOT
Nhung LE
Philippe LIEUTAUD
Ana-Theresa MORAIS
Thi Hong Van NGUYEN
Oney ORTEGA-GRANDA
Nicolas PAPAGEORGIOU
Nadia RABAH
Barbara SELISKO
Ashleigh SHANNON
Coralie VALLE

© AFMB UMR7257  W3C validation